The New Frontier of Longevity Therapeutics: A Physician’s Guide to What the Evidence Actually Shows

Longevity medicine is no longer a fringe interest. It has become one of the most rapidly evolving areas in clinical practice, and the volume of interventions reaching physician desks has grown faster than most clinicians can reasonably evaluate. Patients arrive with questions about NAD+ drips, senolytics, rapamycin, GLP-1 agonists repurposed for aging, cold plunges, and peptide stacks. Some of what they are asking about is backed by compelling mechanistic evidence and emerging clinical data. Some of it is not. Part of what we do at Longevitix is help practitioners separate those two categories, and that starts with honest, evidence-grounded clinical commentary.

Here is my current read on the major therapeutic pathways in longevity medicine, where the evidence stands, and how physicians can engage these interventions with the scientific integrity this field demands.

NAD+ Precursors: Real Biology, Incomplete Translation

The science underlying NAD+ repletion is solid. NAD+ is a coenzyme central to energy metabolism, DNA repair, mitochondrial function, and sirtuin signaling. Intracellular NAD+ levels decline with age across the brain, liver, skin, skeletal muscle, and adipose tissue, and restoring NAD+ content has been shown to reinstate cellular and physiological function in multiple model systems. That much is well-established.

The clinical translation is where the nuance begins. Oral supplementation with NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) reliably elevates NAD+ in blood, and a 2025 systematic review of completed clinical trials published between 2020 and 2025 confirmed that precursor supplementation does increase NAD+ levels across tissues. The problem is that elevated NAD+ has not yet translated consistently into measurable physiological improvements in human trials. Most studies show modest or absent effects on the endpoints that matter clinically, such as cardiovascular function, muscle strength, and cognitive performance, likely due to small sample sizes, variable dosing regimens, and short study durations.

What This Means in Practice

For physicians, this means NAD+ precursors are a reasonable component of a personalized longevity protocol, particularly for older patients with documented metabolic dysfunction, but they should not be framed as proven longevity drugs. Monitoring NAD+ metabolomics alongside inflammatory markers and metabolic panels gives the clinical picture more depth. The signal is real; the dose-response curve and ideal patient profile in humans are still being defined.

Senolytics: Mechanistically Compelling, Clinically Early

Cellular senescence, the process by which cells lose proliferative capacity and develop a pro-inflammatory secretory phenotype (SASP), is one of the established hallmarks of aging. Senolytic agents are designed to selectively clear these cells by transiently disabling the pro-survival pathways that protect them from apoptosis. The most studied combination to date is dasatinib and quercetin (D+Q).

A 2025 pilot study published in eBioMedicine evaluated D+Q in older adults at risk for Alzheimer’s disease. Participants received 100 mg of dasatinib and 1,250 mg of quercetin for two days every two weeks over 12 weeks. No serious adverse events were reported, and there were non-significant improvements in cognitive assessment scores, with 2.0-point significant improvements observed in certain subgroups. Earlier work demonstrated that D+Q reduces senescent cell burden in human adipose tissue and improves physical function in patients with idiopathic pulmonary fibrosis, one of the first direct demonstrations that senolytic therapy clears senescent cells in humans.

Where the Caution Lives

The clinical evidence base for senolytics in healthy aging adults remains at the pilot stage. As promising as the mechanistic rationale is, physicians should not be prescribing senolytics outside of informed, monitored protocols with clear documentation of risk-benefit discussions. The dasatinib component is a tyrosine kinase inhibitor with its own pharmacological profile, and its interaction with patient-specific conditions and medications warrants individual clinical assessment. Fisetin, a naturally occurring flavonoid with senolytic properties, presents a lower-risk alternative for patients not suited to D+Q, though its clinical evidence trail is thinner.

mTOR Inhibitors: The Most Compelling Preclinical Story With the Largest Human Evidence Gap

Rapamycin is the most discussed longevity compound in research circles, and for good reason. mTOR (mechanistic target of rapamycin) sits at a central node in cellular metabolism, governing growth, autophagy, and immune function. A systematic review in The Lancet Healthy Longevity found that rapamycin and its derivatives improved physiological parameters associated with aging in the immune, cardiovascular, and integumentary systems without serious adverse events in healthy individuals, though increases in infections and lipid levels were observed.

The recently published PEARL trial demonstrated that low-dose intermittent rapamycin (5 mg or 10 mg weekly) was well tolerated over one year and produced modest changes in biomarkers of biological aging. It was well tolerated, and females using 10 mg showed significant improvements in lean tissue mass and pain measures. However, an important caveat: the compounded rapamycin used in the trial was approximately 3.5x less bioavailable than commercial formulations, meaning the 5 mg and 10 mg groups effectively received about 1.4 mg and 2.9 mg respectively. That said, as a 2025 review in Aging made clear, human data have not yet established that rapamycin can delay the onset of age-related disease or extend healthspan in a clinically meaningful way. The animal models are extraordinary. The human evidence is early, and the side effect profile, which includes immunosuppression, hyperlipidemia, and hyperglycemia, demands caution.

For practitioners interested in mTOR inhibition as a longevity pathway, the honest position is this: the biology is among the most compelling in the field, the preclinical evidence is strong, and human trials are actively expanding. Prescribing rapamycin off-label requires thorough informed consent, close monitoring, and a clear understanding that this is early-stage clinical territory.

GLP-1 Agonists: The Closest Thing We Have to a Proven Gerotherapeutic

Of all the therapeutic classes discussed in longevity circles today, GLP-1 receptor agonists have the deepest and most rapidly expanding human evidence base. As a November 2025 commentary in Nature Biotechnology put it, two senior scientists from Novo Nordisk and Eli Lilly proposed at the August 2025 Aging Research and Drug Discovery conference in Copenhagen that GLP-1 receptor agonists may be the first longevity drugs, citing their unprecedented efficacy across multiple chronic disease pathways simultaneously.

The cardiovascular data alone is striking. The LEADER, SUSTAIN-6, and SELECT trials demonstrated reductions in major adverse cardiovascular events (MACE) of 13%, 26%, and 20% respectively. Importantly, the SELECT trial confirmed these benefits in individuals with obesity but without diabetes, demonstrating mechanisms beyond glucose control. Beyond cardiovascular protection, a 2025 Lancet Diabetes and Endocrinology meta-analysis pooling 11 trials and over 85,000 participants found that GLP-1 therapies reduced the risk of kidney failure by 16%, slowed filtration decline by 22%, and lowered kidney-related mortality by 19%. While the mechanistic rationale for neuroprotection is robust, the late-2025 results from the EVOKE and EVOKE+ trials provided a critical reality check. In these Phase 3 studies, oral semaglutide failed to meet its primary endpoint of slowing clinical cognitive decline in patients with early-stage symptomatic Alzheimer’s. Despite showing statistically significant improvements in neuroinflammatory biomarkers and pTau levels, the clinical needle didn’t move for patients who already had established pathology. This suggests GLP-1s are likely preventative, not restorative.

Applying GLP-1s in a Longevity Context

For longevity-focused practitioners, GLP-1 agonists are not simply anti-obesity drugs. They modulate nutrient sensing, reduce systemic inflammation, protect vascular endothelium, preserve kidney function, and potentially slow neurodegeneration through multiple pathways simultaneously. The evidence profile makes them a first-line consideration for appropriate patients across metabolic, cardiovascular, and cognitive risk categories. GLP-1s appear most potent when deployed in the ‘pre-symptomatic’ window—targeting metabolic dysfunction before it cascades into irreversible neurodegeneration. For the longevity practitioner, this reinforces their role as a first-line intervention for metabolic and cardiovascular health, even if they aren’t the ‘silver bullet’ for established dementia. The clinical question is not whether to engage this class, but how to integrate it intelligently within an individualized longevity protocol.

Hormetic Protocols: Sauna and Cold Exposure

Not every longevity intervention requires a prescription. Heat and cold exposure activate overlapping and complementary cellular stress pathways, and their evidence base, while largely observational for longevity outcomes, is meaningful.

Research published in Frontiers in Cardiovascular Medicine (2025) confirmed that repeated sauna exposure activates hormetic mechanisms including heat shock protein expression, endothelial nitric oxide synthase upregulation, and NRF2 pathway activation. Large Finnish cohort data show that sauna use four or more times per week is associated with approximately a 50% reduction in cardiovascular mortality compared to once-weekly use, independent of conventional risk factors. Cold exposure activates brown adipose tissue, reduces systemic inflammation, and may complement sauna’s heat shock protein effects through norepinephrine-mediated pathways.

Physicians should feel confident integrating structured heat and cold exposure protocols into patient care plans. In a longevity context, we often discuss the “minimum effective dose.” For sauna, it’s roughly 57 minutes per week (total) to see the start of the mortality curve shift. These are low-risk, evidence-adjacent interventions whose mechanistic plausibility is high and whose safety profile for most healthy adults is excellent. They also engage patients in their own healthspan work in a way that prescription-only protocols cannot.

Building a Clinical Framework That Matches the Evidence

What this landscape requires from physicians is not skepticism toward longevity therapeutics as a category, but calibrated clinical judgment about each intervention’s evidence tier. NAD+ precursors and hormetic protocols belong in personalized protocols now, with appropriate expectations. Senolytics and mTOR inhibitors warrant close clinical supervision and honest risk-benefit discussion. GLP-1 agonists have crossed into mainstream preventive medicine and should be evaluated for any patient carrying metabolic, cardiovascular, or neurocognitive risk.

Dr. David Sinclair of Harvard Medical School has framed this well: “We are at a moment in history where the science of aging is outpacing the clinical infrastructure to deliver it.” That infrastructure gap is precisely what Longevitix was built to close, giving practitioners the tools to translate this emerging evidence into clinical protocols their patients can actually benefit from, safely and consistently.

FAQ

What is the difference between lifespan extension and healthspan extension in longevity medicine?

Lifespan refers to total years lived. Healthspan refers to the years lived in good health, free from significant chronic disease or functional decline. Longevity medicine as a clinical discipline is primarily focused on extending healthspan, compressing the period of morbidity at the end of life, and maintaining physical and cognitive function for as long as possible. Most current therapeutic interventions have more robust evidence for improving healthspan outcomes than for extending total lifespan, and healthspan remains the more clinically meaningful target.

Are NAD+ IV infusions more effective than oral NMN or NR supplementation?

Intravenous NAD+ administration does produce rapid increases in plasma NAD+ levels, but much of it is converted to metabolites through NAD+ glycohydrolase activity before reaching tissues in its intact form. Oral NMN and NR have demonstrated reliable increases in blood NAD+ in clinical trials, and liposomal NMN formulations appear to produce higher NAD+ elevations than standard non-liposomal forms. There is currently no clinical trial evidence demonstrating that IV NAD+ produces superior functional outcomes compared to optimized oral supplementation. For most patients in a longevity clinic setting, oral protocols with appropriate metabolic monitoring are the better-supported approach. Metabolomics testing (measuring intracellular NAD+ vs. NADH) is the emerging way to “prove” the supplement is working, rather than just guessing.

Is rapamycin safe to prescribe off-label for longevity purposes?

The PEARL trial and other small studies suggest that low-dose intermittent rapamycin is well tolerated over one year in healthy adults, with no serious adverse events reported in that population. Known concerns include increased infection risk, elevations in LDL and total cholesterol, and potential hyperglycemia. Prescribing rapamycin off-label for longevity requires a thorough informed consent process, baseline and ongoing monitoring of immune function, lipid panels, and blood glucose, and a clear understanding with the patient that this represents early-stage clinical evidence. It is not appropriate for patients with active infections, impaired immune function, or without access to regular clinical follow-up. Intermittent dosing (e.g., 5-6mg once weekly) is the standard longevity protocol to avoid chronic mTORC2 inhibition (which causes the side effects).

How do senolytics fit into a standard preventive care protocol?

At present, senolytics such as dasatinib plus quercetin are not ready for routine preventive care protocols. The existing evidence supports their safety in monitored pilot settings and demonstrates their ability to reduce senescent cell burden in humans, but large-scale randomized controlled trials establishing clinical efficacy in healthy aging populations are still underway. Physicians interested in incorporating senolytics should do so within structured protocols that include biomarker monitoring, clear documentation of risk-benefit discussions, and appropriate patient selection criteria. Patients with higher baseline senescent cell burden, indicated by elevated inflammatory markers or accelerated biological age scores, represent the more defensible clinical candidates.

What protocols do you recommend for sauna and cold exposure in longevity patients?

The most consistent benefit signals in the sauna literature come from sessions of 15 to 20 minutes at temperatures between 80 and 100 degrees Celsius, practiced four or more times per week. For patients new to heat therapy, starting with two to three sessions per week at shorter durations and building up over four to six weeks is appropriate. Cold exposure protocols vary considerably in the literature; cold water immersion at 10 to 15 degrees Celsius for two to five minutes, practiced three to five times per week, represents a reasonable starting point based on available evidence. Neither intervention should be introduced without considering individual cardiovascular status, and patients with unstable cardiac disease, orthostatic hypotension, or uncontrolled hypertension require individual assessment before starting.

Can GLP-1 agonists like semaglutide treat Alzheimer’s Disease?

“The most recent data from the EVOKE clinical trials indicates that semaglutide does not significantly slow cognitive decline once a patient has reached the early stages of symptomatic Alzheimer’s. However, the ‘biomarker signal’—the drug’s ability to lower neuroinflammation and tau phosphorylation—remained strong. For physicians, this shifts the focus from treatment to risk-reduction. We view GLP-1s as a powerful tool to address the metabolic drivers of cognitive aging (insulin resistance, neuroinflammation, and vascular strain) before clinical symptoms emerge.”

How does Longevitix support physicians in implementing evidence-based longevity protocols?

Longevitix provides clinical infrastructure that allows physicians to move from diagnostic insight to structured, personalized intervention plans without the manual overhead that typically limits longevity practice at scale. The platform integrates data from labs, wearables, EHR systems, genetics, and imaging into a unified clinical view, runs analysis across 15 organ-system expert agents, and generates evidence-linked recommendations through the Clinical Clarity Engine. Every output is editable, traceable to published research, and governed by the Multi-Layer Clinical Safeguard system. Physicians using Longevitix can build and manage structured longevity protocols for their full patient panel while maintaining the individual clinical judgment that makes those protocols meaningful.